Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opioid-Free Pain Control for RARP
NCT04939987Phase 3Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gabapentin, ketorolac, acetaminophen and ketamine in postoperative pain (2 cohorts), sponsored by Wake Forest University Health Sciences. Primary endpoints: Visual Analogue Pain Score at Day 7, Amount of medication used and 1 more. Planned start Aug 2022; status: withdrawn.
02
Drugs
gabapentinketorolacacetaminophenketamine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04939987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939987.